HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White maintains a Buy rating on Inhibikase Therapeutics (NASDAQ:IKT) but lowers the price target from $23 to $15.
August 16, 2024 | 9:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Edward White maintains a Buy rating on Inhibikase Therapeutics but lowers the price target from $23 to $15.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for future performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100